![CheckMate 649_ESMO 2021](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-virtual-congress-2021/screenshots/checkmate-649_esmo-2021/9261621-1-eng-GB/checkmate-649_esmo-2021_i770.jpg)
Upper GI tumours: survival benefits with PD-1 inhibitors plus chemotherapy, but not nivolumab plus ipilimumab
Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours